Sartorius Stedim Biotech and Siemens Sign Long-Term Cooperation Agreement in the Area of Automation

Published: Jun 12, 2018

  • Siemens becomes a preferred supplier for automation solutions
  • Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future
  • New automated product to debut at the ACHEMA 2018 trade show in Frankfurt

The Siemens technology group and Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, have agreed on long-term cooperation in the area of automation. This agreement provides that Sartorius Stedim Biotech will preferably use Siemens automation technologies, which will include industrial PCs, the S7-1500 software controller, the TIA Portal and the SCADA system Simatic WinCC, among others. These hardware and software components will be employed in many products and solutions that SSB offers its customers for the development and manufacture of biopharmaceuticals, such as vaccines and monoclonal antibodies.

Sartorius Stedim Biotech has already been using established Siemens automation solutions for process control in its large-scale bioreactor and filtration systems for quite some time. To standardize its own product portfolio even further, SSB has decided to introduce a new, configurable automation system for its range of systems. Under the agreement recently concluded, cooperation between the two companies will therefore be extended to further Sartorius Stedim Biotech products. These will be successively equipped with Siemens automated solutions in the coming months and can thus be integrated into process control systems, such as Simatic PCS 7 and Simatic Batch. Essentially, such SSB products are single-use bioreactors of the BIOSTAT® STR series, various filtration systems and the FlexAct® system. The latter is a flexible module that is used to control many different process steps within biopharmaceutical production.

“By introducing this new automation platform and further standardizing our products, we are making it easy for our customers to integrate their systems into higher-level automation solutions, such as SCADA, MES or ERP. At the same time, we are enabling them to achieve easier scalability of processes ranging from lab scale to commercial-scale production,” explained Dr. Oscar-Werner Reif, Chief Technology Officer at Sartorius Stedim Biotech. “We have found an ideal partner in Siemens as one of the leading companies in automation,” continued Dr. Reif.

Eckard Eberle, CEO of the Siemens Process Automation business unit, commented: “We are happy to support Sartorius Stedim Biotech with our unique and cohesive portfolio consisting of hardware, software and service throughout the entire system life cycle. Based on our cooperation, users in the biopharmaceutical industry stand to benefit from higher efficiency, quality and flexibility, as well as faster time to market.”

During this year’s ACHEMA trade show that will be taking place from June 11 to June 15, 2018, in Frankfurt, Germany, Siemens and Sartorius Stedim Biotech will be jointly presenting the FlexAct module, a first product based on the new automation platform. Visitors and all others interested are cordially invited to obtain first-hand information at the Siemens AG booth in Hall 11/C3. A presentation on this product will be held in German on June 12 at 1:30 p.m. and in English on June 13 at 1:00 p.m. and on June 14 at 2:00 p.m.

Source: Sartorius Stedim Biotech


Link to the press release

Tweet this press release


About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2017, the company employed approx. 5,100 people, and earned sales revenue of €1,081.0 million.

About Siemens AG
Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for 170 years. The company is active around the globe, focusing on the areas of electrification, automation and digitalization. One of the world’s largest producers of energy-efficient, resource-saving technologies, Siemens is a leading supplier of efficient power generation and power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. With its publicly listed subsidiary Siemens Healthineers AG, the company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2017, which ended on September 30, 2017, Siemens generated revenue of €83.0 billion and net income of €6.2 billion. At the end of September 2017, the company had around 377,000 employees worldwide.

Contacts

Dominic Grone
Corporate Communications
Sartorius Corporate Administration GmbH
+49 (0)551.308.3324
dominic.grone@sartorius.com

Dr. David Petry
Siemens AG
Communications Process Industries and Drives
+49 (9131) 7-26616
david.petry@siemens.com

Back to news